Luu Brendan 4
4 · ENANTA PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Enanta (ENTA) CBO Brendan Luu Receives Equity Awards; Shares Withheld
What Happened
Brendan Luu, Chief Business Officer of Enanta Pharmaceuticals (ENTA), received equity awards that settled into 6,562 shares of Enanta common stock on February 12, 2026 (1,575 shares from PSUs and 4,987 shares from an rTSRU). To cover tax withholding obligations, 3,257 of those shares were automatically forfeited at a withholding price of $14.25 per share, equal to $46,412. The awards were issued at $0 intrinsic purchase price (typical for performance-vested awards).
Key Details
- Transaction dates: Awards settled and withholding occurred on 2026-02-12; Form 4 filed 2026-02-13 (appears timely).
- Awards: 1,575 shares (PSUs) + 4,987 shares (rTSRU) granted/issued (code A, $0.00 per share).
- Withholding/tax payment: 3,257 shares forfeited/disposed (code F) at $14.25 = $46,412.
- Shares owned after transaction: Not specified in the provided filing.
- Footnotes:
- F1: PSUs vested based on two-year R&D milestones for 2024–2025.
- F2: rTSRU vested based on relative total stockholder return vs. Nasdaq Biotech Index over two-year periods.
- F3: The 3,257 shares were automatically forfeited to cover withholding taxes.
- Transaction codes: A = Award/Grant; F = Tax withholding/treatment.
Context
- These were performance-based equity awards that vested and were settled in stock—this is not an open-market purchase or a voluntary sale. The forfeiture is a routine tax-withholding mechanism (often called share-withholding or cashless settlement), not a signal of a separate sale decision.
- For retail investors: awards reflect compensation realization by an executive; withholding to cover taxes is standard practice and does not by itself indicate bullish or bearish insider sentiment.
Insider Transaction Report
Form 4
Luu Brendan
Chief Business Officer
Transactions
- Award
Common Stock
[F1]2026-02-12+1,575→ 39,904 total - Award
Common Stock
[F2]2026-02-12+4,987→ 44,891 total - Tax Payment
Common Stock
[F3]2026-02-12$14.25/sh−3,257$46,412→ 41,634 total
Footnotes (3)
- [F1]Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F2]Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F3]Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Signature
/s/ Matthew Kowalsky as attorney-in-fact|2026-02-13